High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) has announced a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use disorders. This initiative invites interdisciplinary research teams of three to six principal investigators to address critical research questions that could lead to new prevention strategies, treatments, and potential cures for HIV among individuals who use addictive substances. The program emphasizes collaboration and inclusivity, requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) alongside their proposals. Funding is available for up to $3 million over five years, with individual awards capped at $1.5 million per year. Interested applicants should note that a letter of intent is recommended 30 days prior to the application deadline of February 11, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.